Referência de medicamentos
Ponesimod
Ponesimod is a medicine in the class central nervous system. It is used for multiple sclerosis.
- Classe do medicamento: Central Nervous System
- Indicado para: multiple sclerosis
Última atualização
Para profissionais de saúde — apenas referência. Esta página é um resumo breve, não é aconselhamento médico nem substitui a bula oficial ou o julgamento clínico. Verifique sempre antes de prescrever ou dispensar.
O conteúdo clínico desta página está disponível apenas em inglês.
Pontos-chave
- Classe do medicamento
- Central Nervous System
- Código ATC
- L04AE04
- Formas farmacêuticas comuns
- comprimido
- Concentrações comuns
- 20 mg, 2 mg, 10 mg
- Interações conhecidas
- 127 (Contraindicada: 2 · Grave: 46 · Moderada: 71 · Leve: 8)
- Nomes comerciais
- 5
- Países e mercados
- 4
Para que é usado
Como funciona
Sphingosine 1-phosphate (S1P) receptor 1 modulator that binds with high affinity to S1P receptor 1
Dose habitual em adultos (resumo da bula)
Multiple Sclerosis (Initiation) Starter pack must be used for initiating treatment: 2 mg PO qDay initially; increase dose as per dose titration regimen (14-day titration)
Gravidez e amamentação
- Gravidez
- Unsafe EU label: contraindicated in pregnancy. In rats and rabbits it caused fetal death and malformations at clinical exposures without maternal toxicity (S1P receptor role in embryo development); another S1P modulator raised birth-defect risk in humans. Use contraception; stop 1 week before conceiving.
- Amamentação
- Unsafe No human milk data; rat offspring were exposed via milk. US label: weigh benefits; EU label: risk cannot be excluded, should not be used while breastfeeding. LactMed: long half-life and possible infant toxicity; experts advise avoiding the related fingolimod.
Efeitos adversos relatados
- Somnolence
- Elevated hepatic transaminases
- Hypertension
- Urinary tract infection
- Dyspnea
- Dizziness
Contraindicações
- Presence of Mobitz type II second-degree, third-degree AV block, or sick sinus syndrome, unless patient has functioning pacemaker
- In the past 6 months, experienced myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure (HF) requiring hospitalization, or Class III/IV HF
Quem deve ter cuidado
- Consider possibility of severe exacerbation of disease after discontinuing therapy; monitor for severe increase in disability upon discontinuation and appropriately treat; after stopping therapy in the setting of PML, monitor for development of immune reconstitution inflammatory syndrome (PML-IRIS)
- Elevated transaminases may occur; if symptoms (eg, unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, rash with eosinophilia, jaundice, dark urine) occur during therapy, check hepatic enzymes; if significant liver injury confirmed, discontinue therapy
Informe ao farmacêutico ou ao médico sobre gravidez ou amamentação, doença renal ou hepática, alergias e todos os outros medicamentos ou suplementos que você usa.
Principais interações (127)
- Fingolimod + Ponesimod Contraindicated
- Ponesimod + Siponimod Contraindicated
- Amiodarone + Ponesimod Major
- Amisulpride + Ponesimod Major
- Anagrelide + Ponesimod Major
- Anti-thymocyte + Ponesimod Major
- Asenapine + Ponesimod Major
- Atenolol + Ponesimod Major
- Atenolol-chlorthalidone + Ponesimod Major
- Betaxolol + Ponesimod Major
Para assinantes do Pro+
Desbloqueie a página completa
Crie uma conta e comece um teste do Pro+ para abrir a monografia completa de Ponesimod: doses, gravidez e amamentação, efeitos adversos, advertências e todas as interações.
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- Paediatric dosing
- How to give it
- Pharmacokinetics
- Patient counselling points
- Food interactions
Experimente o Pro+ grátis por 14 dias na web. Sem cartão.
Outros medicamentos desta classe
Perguntas frequentes
What is Ponesimod used for?
Ponesimod is a medicine in the class central nervous system. It is used for Multiple sclerosis.
What side effects have been reported with Ponesimod?
Somnolence, Elevated hepatic transaminases, Hypertension, Urinary tract infection, Dyspnea, Dizziness.
Can Ponesimod be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. EU label: contraindicated in pregnancy. In rats and rabbits it caused fetal death and malformations at clinical exposures without maternal toxicity (S1P receptor role in embryo development); another S1P modulator raised birth-defect risk in humans. Use contraception; stop 1 week before conceiving. Breastfeeding: Unsafe. No human milk data; rat offspring were exposed via milk. US label: weigh benefits; EU label: risk cannot be excluded, should not be used while breastfeeding. LactMed: long half-life and possible infant toxicity; experts advise avoiding the related fingolimod.
What does Ponesimod interact with?
MediHelp lists 127 known interactions for Ponesimod. Contraindicated: 2 · Major: 46 · Moderate: 71 · Minor: 8. The most serious include Fingolimod, Siponimod, Amiodarone.
Monografias completas, posologia e verificador de interações no app MediHelp
Abra a referência completa, verifique interações entre vários medicamentos e use as ferramentas de posologia no app MediHelp.
